All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

GSKGlaxoSmithKline
0Calm
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Signing up patientsPhase 3684 patientsMain results: Dec 5, 2029
CADLCandel Therapeutics, Inc.
10Calm
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Running, no new patientsPhase 3711 patientsMain results: Aug 2024
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Signing up patientsPhase 1/260 patientsMain results: Jun 12, 2027
TAKTakeda
5Calm
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Signing up patientsPhase 29 patientsMain results: Oct 28, 2027
PMVPPMV Pharmaceuticals, Inc
0Calm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Signing up patientsPhase 1/2300 patientsMain results: Dec 15, 2026
MRKMerck Sharp & Dohme LLC
5Calm
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Running, no new patientsPhase 1/2180 patientsMain results: Dec 7, 2028
RVMDRevolution Medicines, Inc.
0Calm
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Signing up patientsPhase 3900 patientsMain results: Jun 2028
MRKMerck Sharp & Dohme LLC
5Calm
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Signing up patientsPhase 1/255 patientsMain results: Jul 8, 2031
AZNAstraZeneca
0Calm
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Running, no new patientsPhase 1/26 patientsMain results: Nov 5, 2026
AZNAstraZeneca
0Calm
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Signing up patientsPhase 3100 patientsMain results: Feb 2, 2028
INCYIncyte Corporation
0Calm
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
Not started yetPhase 3590 patientsMain results: May 1, 2032
KPTIKaryopharm Therapeutics Inc
1Calm
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Running, no new patientsPhase 2/3501 patientsMain results: Dec 2026
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Signing up patientsPhase 1/2140 patientsMain results: Aug 17, 2029
RADXRadiopharm Theranostics, Ltd
0Calm
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Signing up patientsPhase 1/261 patientsMain results: Dec 2027
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Signing up patientsPhase 2308 patientsMain results: Sep 3, 2031
GSKGlaxoSmithKline
0Calm
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Signing up patientsPhase 1/264 patientsMain results: Nov 5, 2027
ESLAEstrella Immunopharma, Inc.
14Calm
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Signing up patientsPhase 1/227 patientsMain results: Jul 31, 2027
MRKMerck Sharp & Dohme LLC
5Calm
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Signing up patientsPhase 2180 patientsMain results: Jul 2, 2029
GSKGlaxoSmithKline
0Calm
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Signing up patientsPhase 3690 patientsMain results: May 21, 2030
HCMHutchmed
0Calm
HMPL-A830 in Solid Tumors
Signing up patientsPhase 1/2147 patientsMain results: May 23, 2029
PBYIPuma Biotechnology, Inc.
0Calm
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Signing up patientsPhase 2225 patientsMain results: Dec 30, 2027
KPTIKaryopharm Therapeutics Inc
1Calm
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Running, no new patientsPhase 2244 patientsMain results: Dec 2026
IOVAIovance Biotherapeutics, Inc.
0Calm
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Running, no new patientsPhase 224 patientsMain results: Dec 2027
GSKGlaxoSmithKline
0Calm
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
Signing up patientsPhase 224 patientsMain results: Nov 29, 2027
ABBVAbbVie
1Calm
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Signing up patientsPhase 2377 patientsMain results: Jan 2028